Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call

Rhea-AI Summary

Quotient Limited (NASDAQ:QTNT) will release its fiscal second quarter financial results for the period ending September 30, 2020, on November 2, 2020, before market open. The company will host a conference call at 8:00 a.m. ET the same day, accessible via U.S. and international dialing options. Quotient is known for its proprietary MosaiQ technology, aimed at revolutionizing diagnostics. A COVID-19 antibody test developed by Quotient is CE marked and authorized for use in the U.S., EU, UK, and Switzerland, showcasing its commitment to innovation in diagnostic solutions.

Positive

• Quotient's MosaiQ technology offers a fully automated, consolidated testing platform.
• The MosaiQ COVID-19 Antibody Microarray has received CE marking and Emergency Use Authorization.
• The COVID-19 antibody test is available for distribution in multiple regions including the U.S. and EU.

Negative

• None.

JERSEY, Channel Islands, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2020 will be released before market open on Monday, Nov 2, 2020.

Quotient will host a conference call to discuss its second quarter financial results at 8:00 a.m. Eastern Time the same day. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The access code is 13712034. The conference call will be webcast live on the Company's website at www.quotientbd.com.

A replay of this conference call will be available through November 9, 2020 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13712034.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and is the subject of an Emergency Use Authorization issued by the U.S. Food and Drug Administration. The COVID-19 antibody test is available for distribution in the U.S., the EU, the UK and Switzerland. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

Contact: Peter Buhler, Chief Financial Officer, IR@quotientbd.com; +41 22 545 52 26

FAQ

When will Quotient Limited release its Q2 financial results?

Quotient Limited will release its fiscal second quarter financial results on November 2, 2020, before market open.

What time is the conference call for Quotient's financial results?

The conference call to discuss Quotient's second quarter financial results will take place at 8:00 a.m. Eastern Time on November 2, 2020.

What is the MosaiQ technology from Quotient Limited?

MosaiQ is Quotient's proprietary multiplex microarray technology designed to automate and consolidate testing, improving clinical efficiencies.

Is Quotient's COVID-19 antibody test authorized?

Yes, Quotient's COVID-19 antibody test has received Emergency Use Authorization from the U.S. FDA and is CE marked for distribution.